Trump, Pfizer to announce agreement to lower Medicaid drug prices

Trump, Pfizer to announce agreement to lower Medicaid drug prices


U.S. President Donald Trump speaks during a press conference in the Roosevelt Room at the White House in Washington, D.C., U.S., May 12, 2025.

Nathan Howard | Reuters

President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad.

Trump will announce a drug pricing deal with Pfizer at 11 a.m. ET, a White House official told CNBC’s Eamon Javers. Pfizer CEO Albert Bourla will be in attendance, the official said.

The agreement involves discounted prices in Medicaid and a three-year reprieve on planned pharmaceutical tariffs as long as the company is building manufacturing plants in the U.S., a source told CNBC’s Angelica Peebles.

The deal comes as Pfizer and 16 other drugmakers face Trump’s Monday deadline to take steps to lower drug prices, as outlined in letters from the president.

Pfizer did not immediately respond to a request for comment. The Washington Post first reported the news on Tuesday.

Shares of Pfizer rose more than 3% on Tuesday after the report.

Trump in May signed an executive order reviving a controversial plan, the “most favored nation” policy, that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad.

The deal comes as drugmakers brace for Trump’s planned tariffs on pharmaceuticals imported into the country.

This is breaking news. Please refresh for updates.



Source

Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More
Patient advocacy groups urge U.S. court to halt overseas prescription drug operations
Health

Patient advocacy groups urge U.S. court to halt overseas prescription drug operations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York. Spencer Platt | Getty Images News | Getty Images A coalition of patient advocacy groups is urging a federal court to halt the practices of third-party companies that buy drugs from countries outside the FDA-regulated […]

Read More